Mylan launches generic of Valeant’s Ultram in the US
Published on 29/03/16 at 10:01am
Mylan (NASDAQ, TASE: MYL) has announced the launch of its generic version of Valeant’s Ultram tablets in the US.
The company received final approval from the US Food and Drug Administration for its tramadol hydrochloride extended-release tablets USP, which is indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.
According to IMS Health, tramadol hydrochloride extended-release tablets USP had US sales of approximately $52.8 million for the 12 months to 31st December 2015.
Mylan currently has 265 abbreviate new drug applications pending FDA approval, which represent £110.3 billion in annual brand sales, according to the research body.
Sean Murray
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- Mylan gets provisional FDA greenlight for generic version of Lilly's blockbuster cancer drug Alimta
- FDA approve valsartan generic after shortages of supply
- Mylan's Wixela becomes first FDA-approved generic version of GSK's Advair inhaler
- FDA approves first-ever generic EpiPen versions, courtesy of Teva
- FDA rejects Valeant plaque psoriasis lotion over pharmacokinetic concerns
